GSK Sees One Downside To Size: Co-Promotion Deals Can Be Thorny
The outcome of GlaxoSmithKline's negotiations for the rights to Boehringer Ingelheim's respiratory drug Spiriva illustrates one difficulty for GSK in pursuing licensing agreements to fill out its pipeline.
You may also be interested in...
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials